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ABSTRACT
Triple immunosuppression in renal transplant has drastically changed the outcome of graft survival. However, concern always remains among the 
physicians because of adverse effects produced due to triple immunosuppression. Calcineurin inhibitors are associated with wide range of side effects. 
Hence, we report a case series of tremors associated with tacrolimus among renal transplant patients in a tertiary care hospital in southern India.
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INTRODUCTION
Over past two decades, renal transplantation has become the treatment 
of choice for end-stage renal disease, and it had become a reality with the 
introduction of triple immunosuppressive therapy. In renal transplant, 
survival has increased mainly due to proper perioperative care as well 
treatment with antirejection drugs [1]. The aim of the therapy is to 
prevent graft rejection, and as renal transplant patients require lifelong 
immunosuppression, the side effect of immunosuppression is always a 
problem to combat. Infection being one of the major side effects due to 
lowering of immunity, neurological toxicity with calcineurin inhibitors 
has always been a great challenge to face and it ranges from seizures, 
leukoencephalopathy, coma, but it has always been more in patients 
with lung and liver transplantation when compared to renal transplant 
recipients [2]. Hence, we report a case series of two such cases of 




A 43-year-old male patient after his renal transplantation for stage 
5 chronic kidney disease due to adult polycystic kidney disease was 
started on TAC 5 mg, mycophenolate mofetil 500 mg, wysolone 20 mg, 
valganciclovir 450 mg, and co-trimoxazole single strength (80/400 mg). 
On day 10, the patient’s TAC level was 10.63 ng/ml. Induction therapy 
was not given to this patient. The dose was reduced to 4 mg. On the 
37th day, post-transplant patient came with complaints of tremors on 
both hands. On day 37, TAC level was found to be 9.83 ng/ml. Other 
neurological causes were ruled out, and neurological investigations 
were normal. His vitals were normal, but he had elevated blood 
pressure. Hence, it was confirmed to be TAC toxicity, and dose of TAC 
was maintained at 4 mg. Tremors reduced finally. His final TAC level was 
9.83 ng/ml after his last visit (Table 1).
Case 2
A 55-year-old male patient diagnosed of diabetic nephropathy along 
with ischemic heart disease and hypertension underwent renal 
transplant in the month of December 2016. The patient was given 
induction therapy before transplant with antithymocyte globulin 
100 mg. Post-transplant, he was started with triple suppression with 
TAC 7.5 mg, mycophenolate mofetil 500 mg, wysolone 20 mg along with 
valganciclovir and co-trimoxazole single strength tablet. On day 5, after 
triple immunosuppression, his TAC levels were 14.83 ng/ml following 
which the dose of TAC was reduced to 7 mg. On day 17, he came with 
complaints of tremors on both hands and so, the dose of TAC was 
further reduced to 6.5 mg. Other neurological causes of tremors were 
ruled out, and it was confirmed to be a case of TAC-induced tremors. 
On repeat follow-up on day 26, the patient was fine, and his tremors 
disappeared. His TAC level was found to be 12.11 ng/ml (Table 2).
DISCUSSION
Renal transplantation being the cornerstone in the treatment of 
end-stage renal disease over past few decades, it became very 
successful after the advent of triple immunosuppression therapy. 
Triple immunosuppression consists of a calcineurin inhibitor either 
TAC or cyclosporine, an antiproliferative agent like azathioprine or 
mycophenolate mofetil, and steroids like prednisolone. Induction 
therapy may or may not be given. The main goal of immunosuppression 
is to prevent graft failure due to cell-medicated immunity. However, 
triple immunosuppression being a double-edged sword, side effects 
due to these drug regimens have always been a difficult task for health-
care professionals to combat. Some of the known side effects include 
nephrotoxicity, infections, bone marrow suppression, new onset 
diabetes after transplant, hypertension, weight gain, dyslipidemia, 
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Case Report
Table 1: Case 1 - correlation of tacrolimus levels and dose with 
tremors post-renal transplant
Tacrolimus levels (ng/ml) Tacrolimus 
dose (mg)
Tremors
On day 10-10.63 5 Absent
On day 37-9.83 4 Present
On day 50 (last reading) - 9.83 4 Absent
Table 2: Case 2 - correlation of tacrolimus levels and dose with 
tremors post-renal transplant
Tacrolimus levels (ng/ml) Tacrolimus 
dose (mg)
Tremors
On day 5-14.83 7.5 Absent
On day 17-12.43 7 Present
On day 26 (last reading) - 12.11 6.5 Absent
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and neurotoxicities in various cases [2]. Neurological toxicity 
ranges from tremors, seizures, leukoencephalopathies, and coma 
in rare cases. However, evidence says neurological side effects with 
calcineurin inhibitors are more in patients who undergo liver and lung 
transplantation when compared to renal transplant recipients [3]. 
There are few case reports associated with neurological side effects 
with calcineurin inhibitors post-renal transplantation [4,5]. The 
mechanism by which calcineurin inhibitors cause tremors is by binding 
to calcineurin-binding proteins in central and peripheral nervous 
system and thereby increasing the sympathetic activity. This leads to 
tremors, and evidence also says beta-blocking drugs such as propanol 
are used in the treatment of physiological tremors caused by TAC [6].
In both of our patients, TAC was found to be the causative agent after 
ruling out other neurological causes and other drug-induced side 
effects. Causality assessment was done using Naranjo’s scale, and 
probable causal relationship was established [7]. Severity assessment 
and preventability assessment were done using Hartwig’s scale [8] and 
Thornton’s scale [9], respectively, and it was found to be mild-severe 
and not preventable (Table 3). No treatment was given to these patients, 
and tremors disappeared on the reduction of TAC dose.
CONCLUSION
Since triple immunosuppression is the backbone in renal transplant 
patients, TAC being one among the vital drugs used, adverse drug 
monitoring for TAC toxicity should be of profound concern for the 
treating physicians. Hence, it is prudent enough to monitor TAC level in 
serum and balance the TAC dose accordingly to prevent adverse effects 
and also avoid graft rejection.
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Table 3: Adverse drug assessment
Naranjo’s scale Probable
Hartwig’s scale Mild severity
Thornton’s scale Not preventable
